0.00
price down icon100.00%   -1.17
 
loading
前日終値:
$1.17
開ける:
$0
24時間の取引高:
0
Relative Volume:
0.00
時価総額:
$30.65M
収益:
$16.45M
当期純損益:
$-14.11M
株価収益率:
0.00
EPS:
0.84
ネットキャッシュフロー:
$-11.46M
1週間 パフォーマンス:
-100.00%
1か月 パフォーマンス:
-100.00%
6か月 パフォーマンス:
-100.00%
1年 パフォーマンス:
-100.00%
1日の値動き範囲:
Value
$0.00
$0.00
1週間の範囲:
Value
$0.00
$0.00
52週間の値動き範囲:
Value
$0.00
$3.3994

Ocuphire Pharma Inc Stock (OCUP) Company Profile

Name
名前
Ocuphire Pharma Inc
Name
セクター
Healthcare (1205)
Name
電話
248-681-9815
Name
住所
37000 GRAND RIVER AVE., FARMINGTON HILLS
Name
職員
14
Name
Twitter
Name
次回の収益日
2024-11-11
Name
最新のSEC提出書
Name
OCUP's Discussions on Twitter

OCUP を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
OCUP 0.00 30.65M 16.45M -14.11M -11.46M 0.84
VRTX 467.01 119.87B 10.63B -479.80M -1.35B 13.33
REGN 762.00 83.27B 13.85B 4.65B 3.32B 35.06
ARGX 567.90 33.96B 1.86B -40.29M -1.28B -4.16
ALNY 232.27 30.18B 2.09B -332.26M 16.06M -4.14
BNTX 101.87 24.42B 3.30B -501.07M 1.03B 11.54

Ocuphire Pharma Inc (OCUP) 最新ニュース

pulisher
Nov 16, 2024

FY2024 EPS Estimates for Opus Genetics Cut by HC Wainwright - Defense World

Nov 16, 2024
pulisher
Nov 13, 2024

Opus Genetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com

Nov 13, 2024
pulisher
Oct 25, 2024

The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics - Lelezard

Oct 25, 2024
pulisher
Oct 25, 2024

Ocuphire Pharma Acquires Opus Genetics - Marketscreener.com

Oct 25, 2024
pulisher
Oct 24, 2024

North Carolina gains public company with merger - The Business Journals

Oct 24, 2024
pulisher
Oct 24, 2024

Ocuphire buys Opus Genetics, grows gene therapy pipeline - The Pharma Letter

Oct 24, 2024
pulisher
Oct 24, 2024

Ocuphire Pharma Announces Acquisition of Opus Genetics - Vision Monday

Oct 24, 2024
pulisher
Oct 23, 2024

Ocuphire Shares Rise After Extended US Patent For Nyxol Eye Drops Secured - Marketscreener.com

Oct 23, 2024
pulisher
Oct 23, 2024

Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal - AOL

Oct 23, 2024
pulisher
Oct 23, 2024

Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics - Yahoo Finance

Oct 23, 2024
pulisher
Oct 23, 2024

OCUP stock touches 52-week low at $1.14 amid market challenges - Investing.com UK

Oct 23, 2024
pulisher
Oct 23, 2024

Ocuphire and Opus Genetics merge to develop IRD gene therapy - Yahoo! Voices

Oct 23, 2024
pulisher
Oct 23, 2024

Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders - Business Wire

Oct 23, 2024
pulisher
Oct 23, 2024

Ocuphire Pharma acquires Opus Genetics in all-stock deal By Investing.com - Investing.com Australia

Oct 23, 2024
pulisher
Oct 22, 2024

Ocuphire Pharma acquires Opus Genetics - MSN

Oct 22, 2024
pulisher
Oct 22, 2024

Wilson Sonsini Advises Opus Genetics on IP Matters Related to Acquisition by Ocuphire Pharma - Wilson Sonsini

Oct 22, 2024
pulisher
Oct 22, 2024

Ocuphire Pharma acquires Opus Genetics in all-stock deal - Investing.com

Oct 22, 2024
pulisher
Oct 16, 2024

Presbyopia Market on Track for Major Expansion by 2034, - openPR

Oct 16, 2024
pulisher
Oct 16, 2024

Presbyopia Market on Track for Major Expansion by 2034, According to DelveInsight | Eyenovia, Orasis Pharma, Ocuphire Pharma, Novartis, Visus Therapeutics - The Globe and Mail

Oct 16, 2024
pulisher
Oct 10, 2024

Mydriasis Market Forecasted to Surge in Coming Years, 2024-2034 - openPR

Oct 10, 2024
pulisher
Sep 30, 2024

Ocuphire reports positive phase 3 results for eye treatment RYZUMVI - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

Ocuphire Pharma releases results from MIRA-2 and MIRA-3 clinical trials for phentolamine ophthalmic solution 0.75% for pharmacologically-induced mydriasis - Ophthalmology Times

Sep 30, 2024
pulisher
Sep 30, 2024

Ocuphire reports positive phase 3 results for eye treatment RYZUMVI By Investing.com - Investing.com South Africa

Sep 30, 2024
pulisher
Sep 30, 2024

Ocuphire Pharma Announces Publication of Full Phase 3 - GlobeNewswire

Sep 30, 2024
pulisher
Sep 30, 2024

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology - StockTitan

Sep 30, 2024
pulisher
Sep 24, 2024

OFS Credit Company, Inc. Prices Preferred Stock Offering - Business Wire

Sep 24, 2024
pulisher
Sep 24, 2024

Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch

Sep 24, 2024
pulisher
Sep 24, 2024

OFS Credit to offer preferred stock in public offering - MSN

Sep 24, 2024
pulisher
Sep 24, 2024

Ratio Review: Analyzing Ocugen Inc (OCGN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Sep 24, 2024
pulisher
Sep 24, 2024

Analyzing SOPHiA GENETICS (NASDAQ:SOPH) & Cyclo Therapeutics (NASDAQ:CYTH) - Defense World

Sep 24, 2024
pulisher
Sep 23, 2024

Oaktree Specialty Lending director buys shares worth over $16,000 By Investing.com - Investing.com Canada

Sep 23, 2024
pulisher
Sep 23, 2024

Is OCGN’s price to cash per share ratio a concern for investors? - US Post News

Sep 23, 2024
pulisher
Sep 21, 2024

Option Care Health, Inc. (NASDAQ:OPCH) Position Increased by First Eagle Investment Management LLC - Defense World

Sep 21, 2024
pulisher
Sep 21, 2024

Option Care Health, Inc. (NASDAQ:OPCH) Shares Sold by DekaBank Deutsche Girozentrale - Defense World

Sep 21, 2024
pulisher
Sep 20, 2024

Halozyme's ENHANZE® (HALO) Technology Empowers OCREVUS ZUNOVO™: A New Era in MS Treatment - BP Journal

Sep 20, 2024
pulisher
Sep 20, 2024

Opaleye Management Inc. Increases Stake in Codexis Inc. - Yahoo Finance

Sep 20, 2024
pulisher
Sep 19, 2024

All the Doctor Odyssey guest stars we know so far - Hidden Remote

Sep 19, 2024
pulisher
Sep 18, 2024

Mydriasis Treatment Market Booming Worldwide With Leading Key - openPR

Sep 18, 2024
pulisher
Sep 18, 2024

Full approval of PBC therapy Ocaliva rejected by FDA committee in 10-1 vote - Liver Disease News

Sep 18, 2024
pulisher
Sep 18, 2024

American Century Companies Inc. Raises Position in Option Care Health, Inc. (NASDAQ:OPCH) - Defense World

Sep 18, 2024
pulisher
Sep 17, 2024

Roche’s injectable Ocrevus Zunovo granted FDA approval to treat relapsing and primary MS - PMLiVE

Sep 17, 2024
pulisher
Sep 07, 2024

Ocuphire Pharma, Inc. (OCUP) Reports Q2 Loss, Lags Revenue Estimates - MSN

Sep 07, 2024
pulisher
Sep 06, 2024

Ocuphire Pharma commences phase 3 trial for presbyopia treatment - Investing.com India

Sep 06, 2024
pulisher
Sep 05, 2024

UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia - Yahoo Finance UK

Sep 05, 2024
pulisher
Sep 05, 2024

UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial - GlobeNewswire

Sep 05, 2024
pulisher
Sep 05, 2024

Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% for Presbyopia - StockTitan

Sep 05, 2024
pulisher
Sep 05, 2024

Ocuphire Pharma Inc [OCUP] Chief Scientific & Dev. Ofc. makes an insider purchase of 3,500 shares worth 6178.0. - Knox Daily

Sep 05, 2024
pulisher
Sep 04, 2024

OCUP stock touches 52-week low at $1.15 amid market challenges - Investing.com

Sep 04, 2024

Ocuphire Pharma Inc (OCUP) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Ocuphire Pharma Inc (OCUP) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Magrath George
Chief Executive Officer
May 17 '24
Buy
1.75
5,000
8,772
430,000
SCHACHLE JOSEPH K
Chief Operating Officer
Mar 21 '24
Buy
2.05
2,000
4,100
2,000
Jhaveri Nirav S.
Chief Financial Officer
Mar 21 '24
Buy
2.10
10,000
21,000
150,000
Magrath George
Chief Executive Officer
Mar 18 '24
Buy
1.96
25,000
49,050
425,000
$18.98
price up icon 4.27%
$76.97
price up icon 1.23%
$39.51
price up icon 7.03%
$359.21
price down icon 0.88%
$187.69
price down icon 0.58%
$101.87
price up icon 2.00%
大文字化:     |  ボリューム (24 時間):